Kalydeco (Ivacaftor; VX-770) is a potentiator that increases the open probability of membrane-resident CFTR channels and is approved by the U.S. Food and Drug Administration (FDA) for individuals with responsive gating mutations (~15% of CF patients) [7,8,9]. This evidence concerns the gene CFTR and cystic fibrosis.